FDA Approves Batten Disease Treatment Priced At $702K
The U.S. Food and Drug Administration on Thursday approved Brineura, BioMarin Pharmaceutical Inc.'s treatment for an ultra-rare type of Batten disease, which will reportedly cost about $702,000 per year....To view the full article, register now.
Already a subscriber? Click here to view full article